stockrow
Friday 6 November 2026
Export PRAX’s income statement to Excel — free account
Praxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
274.19
11.60
+4.42%
Follow PRAX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 2 | 9 | — | 9 | +249.5% | 1 | 345 | 1,107 | +3,550.5% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | — | 100.00 | +100.0 pt | ||||||
| EBT | — | — | (26) | (36) | (62) | (167) | (214) | (123) | (183) | (303) | (339) | +41.7% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (5,037.88) | (2,137.48) | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (27) | (36) | (62) | (167) | (214) | (123) | (183) | (303) | (339) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.37 | 0.48 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (306.49) | (398.94) | (117.84) | (59.07) | (69.56) | (18.69) | (10.21) | (13.48) | (12.93) | (36.0%) | ||||||
| Cash flow | — | — | (239.27) | (327.33) | (88.15) | (43.99) | (60.22) | (16.85) | (7.36) | (11.07) | (10.47) | (35.5%) | ||||||
| Capex | — | — | (0.73) | (1.01) | 0.00 | (0.37) | (0.14) | (0.01) | 0.00 | 0.00 | (0.04) | (55.5%) | ||||||
| Free cash flow | — | — | (240.00) | (328.33) | (88.15) | (44.36) | (60.36) | (16.86) | (7.36) | (11.07) | (10.51) | (35.6%) | ||||||
| Book value | — | — | (473.88) | (793.42) | 481.50 | 88.57 | 24.77 | 10.57 | 24.88 | 39.02 | 46.03 | n/m | ||||||
| Shares, m | — | — | 0 | 0 | 1 | 3 | 3 | 7 | 18 | 23 | 26 | +121.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 78.14 | 161.13 | — | 900.80 | 119.6 | ||||||
| P/B | — | — | — | — | — | — | — | 2.74 | 3.09 | — | 5.75 | 2.9 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 44.91 | 115.23 | — | 812.11 | 80.1 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (0.99) | (7.47) | — | (22.69) | (4.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (21) | (33) | (53) | (125) | (185) | (111) | (132) | (249) | (305) | +42.7% | |||||
| Capex | — | — | 0 | 0 | — | (1) | 0 | 0 | — | 0 | (1) | (1.7%) | ||||||
| Free cash flow | — | — | (21) | (34) | (53) | (126) | (185) | (111) | (132) | (249) | (306) | +42.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 14 | 39 | 287 | 249 | 76 | 69 | 367 | 551 | 723 | +69.0% | |||||
| Net debt | — | — | (18) | (45) | (297) | (276) | (100) | (81) | (393) | (599) | (759) | +65.1% | ||||||
| Shareholders’ equity | — | — | (41) | (81) | 287 | 251 | 76 | 70 | 445 | 878 | 1,341 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (294.75) | (120.50) | (40.08) | (56.07) | (104.95) | (121.41) | (64.03) | (42.68) | (36.80) | +252.1 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (236.57) | (73.12) | (40.58) | (73.1) pt | ||||||
| ROE | — | — | 47.89 | 66.67 | (68.13) | (62.07) | (130.94) | (169.13) | (70.98) | (45.83) | (38.86) | (93.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 37 | 67 | 139 | 109 | 82 | 116 | 168 | — | +28.7% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.07 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Dec 2024 · fundamentals updated 26 Oct 2026
Business profile
Praxis Precision Medicines, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | $9.2B | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −108.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KRYS Krystal Biotech, Inc. | $8.9B | 39.2× | 45.7× | +30.21% (above 0%: growing) | −22.26% (below 0%: shrinking) | +137.79% (above 0%: growing) | 94.07% | 55.87% | Compare |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.1B | — (loss-making) | — (loss-making) | +171.02% (above 0%: growing) | n/m | −15.43% (below 0%: shrinking) | 100.00% | (226.03%) | Compare |
| CORT Corcept Therapeutics Incorporated | $7.8B | 47.5× | 39.8× | +63.97% (above 0%: growing) | +525.79% (above 0%: growing) | +160.98% (above 0%: growing) | 98.65% | 33.70% | Compare |
| CYTK Cytokinetics, Incorporated | $7.7B | — (loss-making) | — (loss-making) | +2,356.46% (above 0%: growing) | n/m | −6.73% (below 0%: shrinking) | 0.00% | (351.34%) | Compare |
| ABVX Abivax SA Sponsored ADR | $7.4B | — (loss-making) | — | — | n/m | −48.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PRAX Praxis Precision Medicines, Inc. | $7.3B | — (loss-making) | — (loss-making) | +1,349.13% (above 0%: growing) | n/m | −43.54% (below 0%: shrinking) | 100.00% | 0.00% | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.3B | — (loss-making) | — (loss-making) | +79.59% (above 0%: growing) | n/m | +95.40% (above 0%: growing) | 86.79% | (42.63%) | Compare |
| AXSM Axsome Therapeutics, Inc. | $6.8B | — (loss-making) | — (loss-making) | +51.87% (above 0%: growing) | n/m | −1,078.34% (below 0%: shrinking) | 93.14% | (4.26%) | Compare |
| Median of peers | $7.8B | — | — | +63.97% | — | −11.08% | 89.97% | (2.13%) |
Pay and ownership Proxy statement filed 30 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 8.71m | 55.53m | 35.71 |
| 2024 | 13.43m | 20.64m | 9.33 |
| 2023 | 2.12m | 1.40m | 2.70 |
| 2022 | 6.03m | (17.64m) | 4.33 |
| 2021 | 10.91m | (62.15m) | 35.81 |
Ownership
Directors and executive officers, together
3.00%
Entities affiliated with Janus Henderson Group
9.90%
Entities affiliated with Perceptive Advisors
7.20%
Entities affiliated with Point72
5.50%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Praxis Precision Medicines is a biopharmaceutical company developing treatments for neurological disorders, including essential tremor and epilepsy. It uses insights from the genetics of epilepsy to identify targets involved in how nerve cells communicate. The company was incorporated in 2015, and Marcio Souza is its chief executive officer.
Praxis has not generated revenue from product sales. It has submitted U.S. applications for ulixacaltamide, intended to treat essential tremor, and relutrigine, intended to treat two rare forms of developmental and epileptic encephalopathy, or DEE. DEEs are severe epilepsies that can begin early in life and involve frequent seizures and developmental impairment. Praxis is preparing for potential launches, subject to regulatory approval.